Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Investor Relations

CARA Stock - Cara Therapeutics Stock Trading


home / stock / cara

CARA CARA Quote CARA Short CARA News CARA Articles CARA Message Board

MWN AI Summary *

Cara Therapeutics Inc. (NASDAQ: CARA) is a biopharmaceutical company focused on developing and commercializing innovative therapies for pain and pruritus (itching) based on its proprietary keratinocyte-derived treatment approach. The company’s lead product, KORSUVA™ (difelikefalin), is an injectable selective agonist of the kappa opioid receptor, which has shown promise in managing moderate-to-severe pruritus in patients undergoing hemodialysis, as well as other pain-related conditions.

In July 2021, KORSUVA received approval from the U.S. Food and Drug Administration (FDA) for the treatment of pruritus in adult patients with chronic kidney disease on dialysis, positioning Cara as a key player in addressing significant unmet medical needs within this patient population. The company is also exploring additional indications for KORSUVA, including its potential uses in other types of pruritus and pain management settings.

Cara Therapeutics has been actively advancing its clinical pipeline and has seen a positive market response as its research and development initiatives gain traction. In addition to KORSUVA, the company is working on developing an oral formulation of difelikefalin, which could expand its market reach and application.

Despite the challenges inherent in the biopharmaceutical sector, including competition and regulatory hurdles, Cara Therapeutics has leveraged strategic partnerships and collaborations to bolster its research capabilities and expedite clinical trials. The company’s focus on transformative therapies positions it well for growth, especially as it continues to innovate within the notable areas of pain and itch relief.

Investors are closely monitoring Cara’s progress as it navigates the commercial landscape, with eyes on its financial performance, potential market expansion of KORSUVA, and the development of its pipeline assets. The future growth trajectory of Cara Therapeutics hinges on successful commercialization strategies and positive clinical trial outcomes.

MWN AI Analysis *

Cara Therapeutics Inc. (NASDAQ: CARA) presents a compelling opportunity for investors interested in the biotech sector, particularly with its focus on developing innovative therapies for pain and itching. The company’s lead product, KORSUVA, an injection for pruritus in patients undergoing hemodialysis, has shown promise in clinical trials, providing a solid foundation for revenue growth.

As of October 2023, Cara Therapeutics is poised for potential market expansion with KORSUVA gaining traction in its niche. The recent approval by the FDA has provided a significant lift to investor sentiment, enabling the company to tap into a substantial unmet medical need. The target population for pruritus associated with chronic kidney disease is large, creating a lucrative market for Cara’s therapeutic interventions.

Additionally, Cara is engaged in advancing its pipeline, including oral formulations of KORSUVA, which could enhance its product portfolio and facilitate broader market penetration. Such advancements could bolster revenue streams and mitigate risks associated with reliance on a single product.

However, investors should remain cautious regarding the inherent risks associated with biotech investments. Regulatory challenges, competition within the sector, and execution risks tied to clinical trials and commercial launches can significantly impact Cara’s stock performance.

Current valuations may suggest that the stock is undervalued, particularly if KORSUVA achieves commercial success. Investors should consider establishing positions during potential price fluctuations, while keeping an eye on quarterly earnings, clinical trial results, and market developments that could influence share price.

In conclusion, while Cara Therapeutics presents a promising opportunity with its innovative therapies and a strong market position for KORSUVA, careful analysis and monitoring of industry trends and company performance are essential for informed investment decisions.

* MWN AI Summary and Analysis is based on asking OpenAI to summarize and analyze the company and stock symbol.


About | Cara Therapeutics Inc. (NASDAQ:CARA)

Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

Quote | Cara Therapeutics Inc. (NASDAQ:CARA)

Last:$15.96
Change Percent: -203.95%
Open:$16.17
Close:$15.96
High:$16.56
Low:$15.8436
Volume:237,144
Last Trade Date Time:04/15/2025 03:37:21 pm

News | Cara Therapeutics Inc. (NASDAQ:CARA)

  • CARA announced stock split 1-3

    2025-04-16 09:01:06 ET Cara Therapeutics, Inc. (CARA) announced stock split at a ratio of 1-for-3 on 2025-04-16 ... Full story available on KlickAnalytics.com

    • April 16, 2025 09:01:06 am

    • |
    • KlickAnalytics
    • |
      • CARA Stock
      • CARA Quote
      • CARA Short
      • CARA News
      • CARA Articles
      • CARA Message Board
  • Marijuana Stocks: Top gainers CARA, XLY

    2025-04-14 16:39:29 ET Following are the Top 5 companies based on their one-day percentage change within the 'Marijuana Stocks' theme. Cara Therapeutics, Inc. (CARA) CARA is trading UP for the last 2 days, and it at trading at $5.36 with volume of 87,383 and a one day change of ...

    • April 14, 2025 04:39:29 pm

    • |
    • KlickAnalytics
    • |
      • CARA Stock
      • CARA Quote
      • CARA Short
      • CARA News
      • CARA Articles
      • CARA Message Board

Message Board Posts | Cara Therapeutics Inc. (NASDAQ:CARA)

Subject By Source When
Yeah, good entry room for upwards momentum? WallStreetMyWay investorshub 04/12/2022 4:05:19 PM
Moving up saved its nice growing money nows WallStreetMyWay investorshub 04/12/2022 4:02:57 PM
Got some bounce today. a surfer investorshub 03/02/2022 9:15:22 PM
https://www.benzinga.com/news/earnings/21/11/24060763/you-ask-we-analyze-why-sun BottomBounce investorshub 11/16/2021 4:03:01 PM
$CARA chart conix investorshub 11/15/2021 11:25:36 PM

MWN AI FAQ **

What recent developments in clinical trials for Cara Therapeutics Inc. CARA have shown promise in advancing their innovative treatments for pain management?

Recent clinical trials for Cara Therapeutics Inc. have shown promising results in advancing their therapy, KORSUVA, for acute pain management and pruritus in patients with chronic kidney disease, indicating its potential to significantly enhance pain relief options.

How do the financial results for Cara Therapeutics Inc. CARA in the latest quarter compare to market expectations and previous performance?

In the latest quarter, Cara Therapeutics Inc. (CARA) reported financial results that significantly missed market expectations, reflecting a decline in revenue compared to previous performance, which raised concerns among investors about its growth prospects and overall business strategy.

What partnerships or collaborations has Cara Therapeutics Inc. CARA entered into recently that could enhance their research and development capabilities?

Recently, Cara Therapeutics Inc. entered into a collaboration with Vanda Pharmaceuticals to enhance their research and development capabilities, focusing on advancing their initiatives in pain management and potential novel treatments for various conditions.

How does Cara Therapeutics Inc. CARA plan to navigate potential regulatory challenges as they seek approval for new therapies in the coming year?

Cara Therapeutics Inc. plans to navigate potential regulatory challenges by maintaining transparent communication with regulatory agencies, leveraging their existing clinical data, and strategically engaging with key stakeholders to ensure compliance and support for their new therapies.

** MWN AI Questions are based on asking OpenAI to ask and answer four questions about the company and stock symbol.

Stock Information

Get CARA Alerts

News, Short Squeeze, Breakout and More Instantly...

Cara Therapeutics Inc. Company Name:

CARA Stock Symbol:

NASDAQ Market:

-203.95% G/L:

$15.96 Last:

237,144 Volume:

$16.17 Open:

$15.96 Close:

Cara Therapeutics Inc. Website:

Cara Therapeutics Inc. Logo

Ad

Investor Relations
RECENT CARA NEWS
  • CARA - CARA announced stock split 1-3

    2025-04-16 09:01:06 ET Cara Therapeutics, Inc. (CARA) announced stock split at a ratio of 1-for-3 on 2025-04-16 ... Full story available on KlickAnalytics.com

  • CARA - Marijuana Stocks: Top gainers CARA, XLY

    2025-04-14 16:39:29 ET Following are the Top 5 companies based on their one-day percentage change within the 'Marijuana Stocks' theme. Cara Therapeutics, Inc. (CARA) CARA is trading UP for the last 2 days, and it at trading at $5.36 with volume of 87,383 and a one day change of ...

  • CARA - Marijuana Stocks: Top gainers CRBP, CARA, XLY

    2025-04-11 16:39:41 ET Following are the Top 5 companies based on their one-day percentage change within the 'Marijuana Stocks' theme. Corbus Pharmaceuticals Holdings, Inc. (CRBP) CRBP is trading UP for the last 6 days, and it at trading at $6.03 with volume of 175,452 and a one...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.



Trending Stock Alerts

Trending Stock Alerts

Our Next Stock Alert could be Coming in Minutes!

Sign Up Today To Get Full Access To Our Next Stock Report!

  • Day Before Email and Text Notifications of New Alerts
  • Day of Email and Text Notifications
  • Trending Stocks, Watchlist and News Releases
  • Mobile App Notifications

Trending Stock Alerts

Get CARA Alerts

Get CARA Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.


Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1